-- A more recent data cut will be shared during an oral presentation for the iMMagine-1 study -- -- To date, no delayed neurotoxicities, including no Parkinsonism, no...
Arcellx Inc received a Buy rating and a $129.00 price target from Stifel Nicolaus analyst Stephen Willey today. The company’s shares closed yesterday at $92.37.Elevate Your Investing Strategy: Take advantage...
Canaccord Genuity analyst John Newman maintained a Buy rating on Arcellx Inc today and set a price target of $121.00. The company’s shares closed yesterday at $87.33.Elevate Your Investing Strategy:...
In a report released today, Eric Schmidt FCA from Cantor Fitzgerald maintained a Hold rating on Arcellx Inc. The company’s shares closed yesterday at $88.29.Elevate Your Investing Strategy: Take advantage...
Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Arcellx Inc today and set a price target of $112.00. The company’s shares closed yesterday at $82.24.Elevate Your Investing...
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced...
-- Presented preliminary data from a May 1, 2025 data cutoff date for all 117 patients with a median follow-up of 12.6 months in the Phase 2 pivotal iMMagine-1 study of...
/CNW/ -- Equity Insider News Commentary – With early onset cancer rates on the rise and funding being cut to NIH, the future for cancer patients is...
The S&P 500 Index ($SPX ) (SPY ) today is down -0.13%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.12%. Stocks today are slightly...